Nykredit A S Takes $7.88 Million Position in Labcorp Holdings Inc. $LH

Key Points

• Nykredit A S acquired 28,128 Labcorp shares during the second quarter, establishing a position valued at approximately $7.88 million. Institutional investors collectively own 95.94% of the company.
• Labcorp insiders sold 9,681 shares worth about $3.03 million over the past three months, including CEO Adam Schechter’s $1.50 million sale under a pre-arranged Rule 10b5-1 plan.
• Labcorp exceeded quarterly earnings and revenue estimates, reporting $4.99 in EPS and $3.73 billion in revenue, while analysts maintain a “Moderate Buy” consensus and a $330 target price. The company also declared a quarterly dividend of $0.72 per share.

Nykredit A S acquired a new position in shares of Labcorp Holdings Inc. (NYSE:LH - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 28,128 shares of the medical research company's stock, valued at approximately $7,876,000.

A number of other hedge funds have also bought and sold shares of the company. REAP Financial Group LLC boosted its position in Labcorp by 20.4% during the fourth quarter. REAP Financial Group LLC now owns 218 shares of the medical research company's stock valued at $55,000 after acquiring an additional 37 shares during the last quarter. V Square Quantitative Management LLC lifted its stake in shares of Labcorp by 1.7% in the 1st quarter. V Square Quantitative Management LLC now owns 2,418 shares of the medical research company's stock valued at $645,000 after purchasing an additional 40 shares during the period. Hilltop Holdings Inc. boosted its position in shares of Labcorp by 2.6% during the 4th quarter. Hilltop Holdings Inc. now owns 1,631 shares of the medical research company's stock valued at $409,000 after purchasing an additional 41 shares in the last quarter. Pinnacle Associates Ltd. boosted its position in shares of Labcorp by 3.9% during the 4th quarter. Pinnacle Associates Ltd. now owns 1,126 shares of the medical research company's stock valued at $282,000 after purchasing an additional 42 shares in the last quarter. Finally, Larson Financial Group LLC grew its stake in Labcorp by 37.5% during the third quarter. Larson Financial Group LLC now owns 154 shares of the medical research company's stock worth $44,000 after purchasing an additional 42 shares during the period. Institutional investors own 95.94% of the company's stock.

Insider Transactions at Labcorp

In other news, CEO Adam Schechter sold 4,669 shares of Labcorp stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $320.37, for a total transaction of $1,495,807.53. Following the completion of the transaction, the chief executive officer directly owned 102,565 shares in the company, valued at $32,858,749.05. This trade represents a 4.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Bryan Vaughn sold 234 shares of the business's stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $286.19, for a total transaction of $66,968.46. Following the sale, the executive vice president directly owned 6,746 shares of the company's stock, valued at approximately $1,930,637.74. The trade was a 3.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 9,681 shares of company stock valued at $3,027,677. Corporate insiders own 0.84% of the company's stock.

Labcorp Stock Down 1.4%

LH stock opened at $326.83 on Friday. The stock's 50 day simple moving average is $306.88 and its 200 day simple moving average is $280.62. The company has a market cap of $26.51 billion, a P/E ratio of 27.03, a price-to-earnings-growth ratio of 1.85 and a beta of 0.88. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.53 and a current ratio of 1.80. Labcorp Holdings Inc. has a fifty-two week low of $244.52 and a fifty-two week high of $341.80.

Labcorp (NYSE:LH - Get Free Report) last issued its earnings results on Thursday, July 30th. The medical research company reported $4.99 earnings per share for the quarter, topping analysts' consensus estimates of $4.78 by $0.21. Labcorp had a return on equity of 16.74% and a net margin of 6.99%.The company had revenue of $3.73 billion for the quarter, compared to analyst estimates of $3.71 billion. During the same period in the prior year, the firm earned $4.35 earnings per share. Labcorp's revenue for the quarter was up 5.8% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. On average, research analysts expect that Labcorp Holdings Inc. will post 18.32 earnings per share for the current fiscal year.

Labcorp Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 28th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Friday, August 28th. Labcorp's dividend payout ratio (DPR) is 23.82%.

Wall Street Analyst Weigh In

Several brokerages have issued reports on LH. Wall Street Zen raised Labcorp from a "hold" rating to a "buy" rating in a research note on Sunday, July 12th. Bank of America raised their price objective on shares of Labcorp from $300.00 to $320.00 and gave the stock a "buy" rating in a research report on Monday, July 13th. Weiss Ratings upgraded shares of Labcorp from a "buy (b-)" rating to a "buy (b)" rating in a research note on Friday, July 24th. Truist Financial increased their target price on shares of Labcorp from $320.00 to $350.00 and gave the stock a "buy" rating in a research note on Friday, July 31st. Finally, Morgan Stanley raised their price target on shares of Labcorp from $308.00 to $338.00 and gave the stock an "overweight" rating in a report on Friday, July 31st. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $330.00.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp NYSE: LH, is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp's core businesses encompass clinical laboratory testing and pharmaceutical development services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source